Sessions Designed for Series A & Post-Series A Companies

Preparing for Structuring and Negotiating M&A in MedTech
Room 301 | 9:15-10:30 a.m. & 10:45-noon

Understand how deals are structured, what terms matter most, and where founders commonly lose value. This session provides a practical look at navigating negotiations, the impact of IP ownership, coding, and reimbursement on valuation, and strategies to align these elements to maximize outcomes.

From Build to Billable: Scaling Product, Manufacturing, and Market Adoption
Room 304 | 9:15-10:30 a.m. & 10:45-noon

You’ve built the product, now you must scale and sell it. This session is designed for Series A and post-Series A MedTech companies navigating the transition from development to commercialization. Led by a joint team from Remedy Medical and Auer Medical, it will focus on aligning product design with manufacturing, scaling production, and building the operational and commercial pathways needed to drive adoption in health systems. Founders will gain practical insight into avoiding common scale-up pitfalls, navigating value analysis committees, and converting early clinical interest into real revenue.

Proof to Partnership: De-Risking Your Startup to Attract Capital and Strategic Partners
Room 305 | 9:15-10:30 a.m. & 10:45-noon

In healthcare, progress isn’t measured by ideas; it’s measured by proof. This session focuses on how to translate early validation into strategic partnerships, capital, and real commercial momentum. We’ll walk through how to de-risk your company across clinical, regulatory, and market dimensions, while aligning your business development efforts with what investors and industry partners are actually looking for. Attendees will leave with a clear, strategic framework to move from initial proof points to meaningful partnerships, smarter capital decisions, and a more efficient path to market.

Coverage to Cash Flow: Building Trust with Physicians, Scaling Reimbursement, Market Access, and Revenue Growth 
Room 306 | 9:15-10:30 a.m. & 10:45-noon

Reimbursement isn’t just about access, it’s about accelerating revenue and driving scale—and that starts with physician adoption. This session focuses on how growth-stage MedTech companies move from initial coverage to consistent, repeatable cash flow by building trust with clinicians who ultimately drive utilization and navigate the reimbursement pathway.

PRS Network will break down strategies for positioning unlisted codes vs. Category III CPT pathways, optimizing coding and payment, expanding payer coverage, navigating value analysis committees, and aligning pricing with real-world economics. Learn how to remove friction for physicians, avoid revenue bottlenecks, and translate clinical adoption into predictable, scalable growth.

Sessions Designed for Pre-Seed & Seed Companies

From Code to Cash: The Economics Behind Adoption, Reimbursement, and Real-World Value
Room 301 | 1:45-3 p.m. & 3:15-4:30 p.m.

Great technology doesn’t win in healthcare; reimbursement does. This session breaks down how coding, coverage, and payment drive real-world adoption of medical devices. PRS Network will share how to align early with reimbursement pathways, avoid costly missteps, and position your solution for faster uptake with providers and health systems. Attendees will leave with a clear understanding of how to turn clinical value into sustainable revenue.

From Sketch to Scale: Laying the Foundation for Development & Manufacturing
Room 304 | 1:45-3 p.m. & 3:15-4:30 p.m.

Great ideas are easy, building something that can actually be manufactured and meet medical device requirements is not.  This session is designed for pre-seed and seed-stage MedTech founders working to turn early concepts into real, manufacturable products. Jointly led by Remedy Medical and Auer Medical, it will focus on making the right early decisions in product design, prototyping, and development to ensure a clear path through development to early manufacturing and scale. Founders will gain practical insight into avoiding costly missteps, aligning design with production realities, and building with the end in mind from day one.

Regulatory Pathways 101: Choosing the Right Route for Drugs, Biologics, Devices, Diagnostics, and Digital Health
Room 305 | 1:45-3 p.m. & 3:15-4:30 p.m.

In the fast-moving world of urologic innovation, great science alone isn’t enough – you need the right regulatory strategy to reach patients and secure funding.  We will break down major FDA pathways, common pitfalls, and smart early decisions that can save you time, money and headaches.  We will demystify the FDA playbook, and walk through key routes for drugs, biologics, devices, diagnostics, and digital health- including when to pursue a 510(k), De Novo, PMA, Breakthrough Designation, IND/NDA, or newer digital health frameworks.

The Biggest (and Most Expensive) Mistakes Founders Make
Room 306 | 1:45-3 p.m. & 3:15-4:30 p.m.

From filing patents too early to considering reimbursement too late, this roundtable will break down the most common - and costly - strategic missteps startups in the medtech/device space can make. Polsinelli attorneys share real-world examples of how mistakes across IP, reimbursement, and funding decisions can lead to wasted capital, down rounds, or stalled adoption and what companies should do differently to avoid those outcomes.